New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust…
Six months' follow-up of prevention trial showed 83 per cent reduced risk of symptomatic COVID-19, with no severe disease or…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.